Fewer ultrasounds and biopsies were seen for women referred for breast tomosynthesis after recall for focal asymmetric density following screening mammography.
Performing breast tomosynthesis among women recalled for focal asymmetric density after a screening mammography results in fewer ultrasounds, fewer biopsies and higher positive predictive value (PPV) for cancer, according to a study presented today at the 2014 ARRS Annual Meeting in San Diego, Calif.
“Tomosynthesis has been evaluated in screening populations and been shown to decrease recall rates, but studies in the diagnostic setting are lacking,” researcher Brandi Nicholson said in a release.
To address this issue, researchers from the University of Virginia in Charlottesville compared tomosynthesis to 2D diagnostic imaging for 532 women recalled for a focal asymmetric density (FAD) at screening. The researchers retrospectively reviewed patients who had been recalled from screening for both one and two view FAD in three groups: 238 in the pre-tomo group (PT) from July to October 2011, 145 in a no-tomo (NT) and 149 in a yes-tomo (YT) group from April to July 2012 imaged and interpreted at their institution. Tomo imaging was dual acquisition.
The findings showed that ultrasounds were performed significantly less often in the YT group than in both the PT group and the NT group. However the number of ultrasounds was similar for the PT and NT groups. In addition, the researchers found that the PPV was increased in the YT group, compared with both the PT and NT groups.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 2
July 23rd 2025In the second part of a multi-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, discuss key sequences for abbreviated breast MRI and how it stacks up to other breast cancer screening modalities.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.